Pharmaceutical composition used in kit for treating cancer, e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer, comprises tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or antiprotozoal drugs optionally along with the excipients
2023-10-04
专利权人MANKIND PHARMA LTD (MANK-Non-standard)
申请日期2023-10-04
专利号IN202311066521-A
成果简介NOVELTY - Pharmaceutical composition comprises: tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor or antiprotozoal drugs optionally along with one or more excipients. USE - Pharmaceutical composition used in kit for treating cancer (all claimed), e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer. Test details are described but no results given. ADVANTAGE - The pharmaceutical composition exhibits synergistic effect; improve bioavailability, and ease of administration. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: 1. a pharmaceutical combination for cancer, which comprises: dasatinib, simvastatin or quinacrine; and 2. a kit, which comprises: (a) composition comprising dasatinib and excipients; (b) composition comprising quinacrine or simvastatin and excipients; where composition of dasatinib, composition of quinacrine or simvastatin are administered either simultaneously, concurrently, alternately or sequentially.
IPC 分类号A61K-031/277 ; A61K-031/404 ; A61K-031/506 ; A61K-045/06 ; A61P-035/02 ; A61P-043/00
国家印度
专业领域医药卫生
语种英语
成果类型专利
文献类型科技成果
条目标识符http://119.78.100.226:8889/handle/3KE4DYBR/20135
专题中国科学院新疆生态与地理研究所
作者单位
MANKIND PHARMA LTD (MANK-Non-standard)
推荐引用方式
GB/T 7714
KUMAR A,RAI S K,KUMAR R. Pharmaceutical composition used in kit for treating cancer, e.g., breast cancer, melanoma, colorectal cancer, non-small cell lung cancer, comprises tyrosine kinase inhibitor and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor or antiprotozoal drugs optionally along with the excipients. IN202311066521-A[P]. 2023.
条目包含的文件
条目无相关文件。
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。